COVID-19 and protection of vaccination in patients with systemic sclerosis-associated interstitial lung disease.

Stylianos T PanopoulosVasilios TzilasVasiliki-Kalliopi BourniaAnastasios KaramanakosKaterina LaskariDemosthenes BourosMaria TektonidouPetros P Sfikakis

Published in: Journal of scleroderma and related disorders (2022)

SARS-CoV-2 vaccination is of outmost importance for every systemic sclerosis patient with interstitial lung disease. COVID-19 does not seem to promote progression of systemic sclerosis-associated interstitial lung disease in vaccinated patients, but further studies are warranted.

Keyphrases

systemic sclerosis
interstitial lung disease
sars cov
coronavirus disease
respiratory syndrome coronavirus
end stage renal disease
newly diagnosed
rheumatoid arthritis
ejection fraction
prognostic factors